Relapsed/Refractory Multiple Myeloma: Switching Therapy

Considerations for switching between IMiD-based therapy and proteasome inhibitors, as well as incorporating in a monoclonal antibody to a patient with relapsed and refractory multiple myeloma’s treatment.